Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 9/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14273278 | 0.87 | CDK8 (0.54) | CDK8RAF1BRAFTRPV1HDAC3 | |
| SCHEMBL5116674 | 0.86 | CDK8 (0.49) | KDRCDK8RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3989166 | 0.85 | RAF1 (0.70) | KDRCDK8RAF1BRAFHDAC3 | |
| SCHEMBL3994618 | 0.84 | RAF1 (0.54) | KDRCDK8RAF1BRAFTRPV1 | |
| SCHEMBL14266620 | 0.84 | RAF1 (0.56) | KDRCDK8RAF1BRAFTRPV1 | |
| SCHEMBL5131076 | 0.82 | RAF1 (0.56) | KDRCDK8RAF1BRAFTRPV1 | |
| SCHEMBL5131078 | 0.82 | RAF1 (0.56) | KDRCDK8RAF1BRAFTRPV1 | |
| SCHEMBL5123281 | 0.81 | RAF1 (0.59) | KDRCDK8RAF1BRAFTRPV1 | |
| SCHEMBL5123286 | 0.81 | RAF1 (0.59) | KDRCDK8RAF1BRAFTRPV1 | |
| SCHEMBL4100756 | 0.81 | CDK8 (0.51) | KDRCDK8RAF1BRAFTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061761-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | Millennium Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2008030448-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030448-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MAP4K5, MAP3K5, MAP4K2 | KDR 1073/4885CDK8 369/4885RAF1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.